TrialJournal of diabetes investigation2016

Long-term safety and efficacy of a novel once-weekly oral trelagliptin as monotherapy or in combination with an existing oral antidiabetic drug in patients with type 2 diabetes mellitus: A 52-week open-label, phase 3 study.

Nobuya Inagaki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.